TABLE 3

Change from the PATENT-1 study baseline during the PATENT-1 study and the PATENT-2 study

	Former riociguat 2.5 mg maximum			Former riociguat 1.5 mg maximum			Placebo			Total population PATENT-2 1 year
	PATENT-1 week 12	PATENT-2		PATENT-1 week 12	PATENT-2		PATENT-1 week 12	PATENT-2
	PATENT-1 week 12	Week 12	1 year	PATENT-1 week 12	Week 12	1 year	PATENT-1 week 12	Week 12	1 year
NT-proBNP
Observed values pg mL^-1	−338±1031	−322±1206	−291±1612	−447±954	−520±944	−235±1214	134±809	−410±1023	−294±1945	−284±1653
Patients	207	201	177	46	46	44	95	93	80	301
Borg dyspnoea score
Observed values	−0.55±1.52	−0.58±1.84	−0.52±1.98	−0.43±1.19	−0.52±1.64	−0.18±1.58	−0.15±1.88	−0.54±1.90	−0.45±2.06	−0.45±1.94
Patients	228	218	192	55	54	49	108	102	84	325
EQ-5D score
Observed values	0.05±0.21	0.06±0.22	0.06±0.24	0.10±0.26	0.15±0.24	0.13±0.24	0.02±0.22	0.03±0.24	0.07±0.20	0.07±0.23
Patients	227	212	193	55	52	50	106	102	83	326
LPH score
Observed values	−7.6±16.8	−11.0±18.9		−11.8±16.1	−14.3±18.9		−2.7±15.1	−2.1±15.7
Patients	224	209^#		55	54^#		105	93^#

Data are presented as mean±sd or n. NT-proBNP: N-terminal prohormone of brain natriuretic peptide; EQ-5D: Euro Qol Group 5-Dimension Self-Report Questionnaire. ^#: Week 8 data shown for Living with Pulmonary Hypertension (LPH) score.